Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Wedgewood Investors Inc. PA

Wedgewood Investors Inc. PA cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,075 shares of the medical research company’s stock after selling 50 shares during the period. Wedgewood Investors Inc. PA’s holdings in Thermo Fisher Scientific were worth $313,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of TMO. Brinker Capital Inc. grew its stake in Thermo Fisher Scientific by 0.5% during the 3rd quarter. Brinker Capital Inc. now owns 28,018 shares of the medical research company’s stock worth $8,162,000 after purchasing an additional 135 shares in the last quarter. Candriam Luxembourg S.C.A. grew its stake in Thermo Fisher Scientific by 11.3% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 104,069 shares of the medical research company’s stock worth $30,000 after purchasing an additional 10,569 shares in the last quarter. Avitas Wealth Management LLC grew its stake in Thermo Fisher Scientific by 1.3% during the 3rd quarter. Avitas Wealth Management LLC now owns 14,483 shares of the medical research company’s stock worth $4,218,000 after purchasing an additional 189 shares in the last quarter. Whittier Trust Co. grew its stake in Thermo Fisher Scientific by 0.4% during the 3rd quarter. Whittier Trust Co. now owns 48,260 shares of the medical research company’s stock worth $14,056,000 after purchasing an additional 180 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its stake in Thermo Fisher Scientific by 2.8% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 20,369 shares of the medical research company’s stock worth $5,933,000 after purchasing an additional 559 shares in the last quarter. 88.21% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Director Jim P. Manzi sold 1,833 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $272.93, for a total transaction of $500,280.69. Following the transaction, the director now owns 28,592 shares of the company’s stock, valued at approximately $7,803,614.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 2,271 shares of the stock in a transaction on Friday, September 13th. The stock was sold at an average price of $298.00, for a total value of $676,758.00. Following the transaction, the chief executive officer now directly owns 283,502 shares in the company, valued at approximately $84,483,596. The disclosure for this sale can be found here. In the last quarter, insiders sold 54,104 shares of company stock worth $15,418,539. Insiders own 0.45% of the company’s stock.

NYSE:TMO traded up $2.41 on Monday, reaching $283.84. 530,513 shares of the company’s stock were exchanged, compared to its average volume of 1,674,887. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.49 and a quick ratio of 1.07. The firm has a market cap of $112.77 billion, a price-to-earnings ratio of 25.52, a P/E/G ratio of 1.84 and a beta of 1.13. Thermo Fisher Scientific Inc. has a 52 week low of $208.34 and a 52 week high of $305.45. The stock has a fifty day simple moving average of $288.69 and a 200-day simple moving average of $281.30.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share for the quarter, topping analysts’ consensus estimates of $3.01 by $0.03. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.11%. The firm had revenue of $6.32 billion during the quarter, compared to analyst estimates of $6.31 billion. During the same quarter last year, the business earned $2.75 earnings per share. The company’s quarterly revenue was up 3.9% on a year-over-year basis. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 12.25 EPS for the current year.

Several research analysts have recently issued reports on TMO shares. ValuEngine cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Credit Suisse Group reaffirmed a “buy” rating and set a $310.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, July 31st. Barclays set a $330.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Monday, July 15th. Finally, Needham & Company LLC upped their price objective on Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $305.27.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Further Reading: Commodities

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.